Oak Thistle LLC Purchases New Shares in Encompass Health Co. (NYSE:EHC)

Oak Thistle LLC bought a new position in Encompass Health Co. (NYSE:EHC - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 22,726 shares of the company's stock, valued at approximately $2,099,000. Encompass Health makes up 0.6% of Oak Thistle LLC's portfolio, making the stock its 23rd largest holding.

Other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Encompass Health by 0.7% in the 3rd quarter. State Street Corp now owns 3,025,769 shares of the company's stock worth $292,410,000 after purchasing an additional 21,329 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Encompass Health by 1.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,819,345 shares of the company's stock worth $156,083,000 after buying an additional 22,311 shares during the last quarter. Geode Capital Management LLC boosted its stake in Encompass Health by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company's stock worth $161,781,000 after buying an additional 20,547 shares in the last quarter. Copeland Capital Management LLC grew its position in Encompass Health by 1.0% during the third quarter. Copeland Capital Management LLC now owns 1,284,550 shares of the company's stock valued at $124,139,000 after acquiring an additional 12,433 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Encompass Health by 2,458.5% during the third quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company's stock worth $83,990,000 after acquiring an additional 835,135 shares in the last quarter. Institutional investors own 97.25% of the company's stock.

Encompass Health Trading Up 0.6 %

EHC traded up $0.53 during midday trading on Wednesday, reaching $93.59. 352,465 shares of the company's stock traded hands, compared to its average volume of 578,052. Encompass Health Co. has a 52 week low of $67.94 and a 52 week high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a fifty day moving average of $97.91 and a two-hundred day moving average of $93.88. The stock has a market capitalization of $9.43 billion, a price-to-earnings ratio of 22.61, a P/E/G ratio of 1.30 and a beta of 0.89.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.86 earnings per share. On average, equities analysts anticipate that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health's payout ratio is 16.43%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Barclays upped their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a research note on Tuesday, October 29th. Royal Bank of Canada upped their price target on shares of Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. UBS Group lifted their price objective on Encompass Health from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Truist Financial restated a "buy" rating and set a $116.00 target price (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Finally, KeyCorp raised their price target on Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 29th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.